By targeting the weaknesses of ATM-deficient cancer cells, this approach not only boosts the effectiveness of ATR inhibitors but also introduces a promising strategy to overcome chemoresistance, paving the way for more innovative and effective treatments for colorectal cancer.315. This evidence concerns the gene ATM and colorectal cancer.